Impilo acquires Oticon Medical in €80m deal to drive standalone growth
Impilo, a Nordic investment firm, has acquired Oticon Medical from Demant for up to DKK600m (US$92.7m). The deal, worth around €80m, sees Impilo invest the full amount from its recently raised Fund II. Demant will use the proceeds to boost its cash reserves and reduce gearing.
Under Demant's ownership, Oticon Medical gained a strong reputation for innovation and clinical excellence in bone-anchored hearing solutions. Søren Nielsen, Demant's CEO, expressed confidence in Oticon Medical's continued success under Impilo's ownership.
Impilo will support Oticon Medical's transition to a standalone company and accelerate its growth. Magnus Edlund, a partner at Impilo, expressed delight in partnering with Oticon Medical's management on the acquisition. René Govaerts, Oticon Medical's general manager, welcomed Impilo's partnership, expecting it to drive global growth and new innovations.
The total purchase price consists of DKK325m paid in cash at closing, with the remaining amount contingent upon achieving certain targets and milestones.
Impilo's acquisition of Oticon Medical marks the first investment from its Fund II, raised at the hard cap of €700m. Demant will assist Impilo during the transition, ensuring a smooth move to a stand-alone business.
